Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2023-174242

Published: 2023

Journal Articles

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Santiago Montes-Moreno, Sr., Aitana Avendaño, Sonia Gonzalez De Villambrosia, Laura Rodriguez-Merino, Jordi Morata, Raul Tonda, Estrella Carrillo-Cruz, Carlos Grande, Jose Maria Roncero, Jaime Perez De Oteyza, Concepcion Nicolas, Beatriz Rey Búa, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez, Alejandro Martin Garcia-Sancho, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2023-179150

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Blood (2023) 142 (Supplement 1): 786.

https://doi.org/10.1182/blood-2023-186730

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu

Blood (2023) 142 (Supplement 1): 668.

https://doi.org/10.1182/blood-2023-180175

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Cecilia Carpio, Manjusha Namuduri, Nazia Iqbal, Dishan Liu, Nickolas Sophos, Min Zhu, Ayesha Sabir, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Alejandro Martín García-Sancho

Blood (2023) 142 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2023-179964

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Blood (2023) 142 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2023-186952

Published: 2023

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Jason Westin, Alejandro Martín García-Sancho, Marc Hoffmann, Theodoros P. Vassilakopoulos, Su-Peng Yeh, Argyrios Gkasiamis, Poliana Patah, Arpankumar Patel, Ju Li, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 9475–9477.

https://doi.org/10.1182/blood-2022-162774

Published: 2022

Journal Articles

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Mariana Bastos-Oreiro, Ana Jimenez-Ubieto, Sonia González de Villambrosia, Raul Cordoba, Elena Pérez Ceballos, EVA Maria DONATO Martin, Ana Muntañola Prat, Hugo Daniel Luzardo Henriquez, Lourdes Escoda, Maria Jesús Peñarrubia, María Pozas, Alberto Lopez-Garcia, Daniel Garcia, Emilia Pardal, Claudia Salazar Lozada, Alejandro Martín García-Sancho

Blood (2022) 140 (Supplement 1): 9501–9503.

https://doi.org/10.1182/blood-2022-166213

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro

Blood (2022) 140 (Supplement 1): 779–781.

https://doi.org/10.1182/blood-2022-170854

Published: 2022

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

NARROW

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only